Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOPREDICT: Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy for Borderline Pancreatic Cancer
NCT07616362Phase 2Not yet recruiting
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jun 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, paclitaxel in pancreatic ductal adenocarcinoma (PDAC), sponsored by Fédération Francophone de Cancérologie Digestive. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07616362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07616362.